Lincoln Pharmaceuticals Ltd: Valuation Shifts Signal Changing Price Attractiveness

Valuation Metrics: From Attractive to Fair

As of 13 February 2026, Lincoln Pharmaceuticals trades at a P/E ratio of 13.78, a figure that has contributed to its reclassification from an attractive to a fair valuation grade. This P/E multiple is notably lower than many of its peers in the Pharmaceuticals & Biotechnology sector, where companies such as Bliss GVS Pharma and Syncom Formulations command P/E ratios of 20.82 and 21.26 respectively. However, it is significantly higher than the sector’s historically low valuation levels for Lincoln, which had previously positioned the stock as undervalued.

The price-to-book value ratio stands at 1.69, indicating that the stock is trading at a modest premium to its book value. This P/BV ratio aligns with the fair valuation grade and suggests that investors are pricing in moderate growth expectations and stable asset quality. The enterprise value to EBITDA (EV/EBITDA) ratio of 9.83 further supports this assessment, placing Lincoln comfortably below several peers classified as very expensive, such as Shukra Pharmaceuticals with an EV/EBITDA of 52.05.

Comparative Peer Analysis

When benchmarked against its peer group, Lincoln Pharmaceuticals exhibits a more conservative valuation profile. For instance, NGL Fine Chem and Hester Biosciences are trading at EV/EBITDA multiples of 25.13 and 21.55 respectively, reflecting higher growth expectations or premium market positioning. Conversely, companies like TTK Healthcare and Bajaj Healthcare maintain attractive valuations with P/E ratios of 18.97 and 22.33, but their EV/EBITDA multiples are considerably higher, indicating differing capital structures or profitability profiles.

Lincoln’s PEG ratio remains at 0.00, which may indicate either a lack of meaningful earnings growth projections or data unavailability. This contrasts with peers such as Bliss GVS Pharma and Kwality Pharmaceuticals, which have PEG ratios of 0.87 and 0.38 respectively, suggesting moderate growth priced into their valuations.

Financial Performance and Returns

Lincoln Pharmaceuticals’ return on capital employed (ROCE) stands at a robust 17.79%, while return on equity (ROE) is 11.18%. These figures demonstrate efficient utilisation of capital and reasonable profitability, supporting the fair valuation grade. The dividend yield remains modest at 0.30%, indicating limited income return for investors but potentially signalling reinvestment into growth or operational expansion.

Examining stock performance relative to the Sensex reveals a mixed picture. Over the past week and month, Lincoln has outperformed the benchmark significantly, with returns of 31.16% and 25.02% respectively, compared to Sensex’s 0.43% and -0.24%. Year-to-date, the stock has gained 25.08%, while the Sensex declined by 1.81%. However, over the one-year horizon, Lincoln underperformed with a negative return of -8.51% against the Sensex’s 9.85% gain. Longer-term returns remain impressive, with five- and ten-year returns of 175.10% and 287.19%, well above the Sensex’s 62.34% and 264.02% respectively.

Market Capitalisation and Grade Evolution

Lincoln Pharmaceuticals currently holds a market cap grade of 4, reflecting its mid-cap status within the Pharmaceuticals & Biotechnology sector. The company’s Mojo Score stands at 40.0, with a Mojo Grade of Sell, upgraded from a previous Strong Sell rating on 5 August 2025. This upgrade signals improving investor sentiment and a stabilisation in valuation metrics, although caution remains warranted given the fair valuation status and sector volatility.

The stock’s recent price action has been volatile, with a day change of 13.81% and intraday trading ranging between ₹488.00 and ₹637.25. The current price of ₹604.40 is closer to its 52-week high of ₹707.90 than the low of ₹439.95, indicating a recovery phase after a period of consolidation.

Sector Context and Valuation Implications

The Pharmaceuticals & Biotechnology sector continues to face headwinds from regulatory scrutiny, pricing pressures, and evolving market dynamics. Within this context, Lincoln Pharmaceuticals’ shift from an attractive to a fair valuation grade suggests that the market is factoring in these challenges while recognising the company’s solid fundamentals and growth prospects.

Investors should note that while Lincoln’s valuation metrics remain reasonable compared to many peers, the absence of a PEG ratio and modest dividend yield imply limited near-term growth visibility and income generation. The company’s strong ROCE and ROE provide some reassurance on operational efficiency and capital utilisation, but the fair valuation grade indicates that the stock is no longer a bargain buy.

Investor Takeaway

Lincoln Pharmaceuticals Ltd’s recent valuation shift to a fair grade reflects a maturing market view that balances the company’s solid financial metrics against sector challenges and competitive pressures. The stock’s P/E ratio of 13.78 and P/BV of 1.69 suggest reasonable pricing relative to earnings and book value, but investors should be mindful of the limited growth visibility indicated by the PEG ratio and modest dividend yield.

Comparisons with peers reveal that Lincoln remains competitively valued, especially against very expensive stocks in the sector. Its strong ROCE and ROE underpin operational strength, while recent price gains demonstrate renewed investor interest. However, the downgrade from a Strong Sell to a Sell Mojo Grade advises a cautious approach, with potential upside tempered by sector risks and valuation normalisation.

Long-term investors may find value in Lincoln’s consistent capital returns and relative outperformance over multi-year horizons, but short-term traders should monitor volatility and sector developments closely. Overall, the stock’s fair valuation status suggests it is fairly priced for current fundamentals, neither a clear bargain nor an overvalued risk.

Historical Price and Return Context

Lincoln Pharmaceuticals’ stock price has demonstrated resilience over extended periods, with a 3-year return of 83.93% and a 5-year return of 175.10%, substantially outperforming the Sensex’s 37.89% and 62.34% respectively. The 10-year return of 287.19% also surpasses the Sensex’s 264.02%, highlighting the company’s long-term growth trajectory.

However, the recent one-year return of -8.51% contrasts with the Sensex’s positive 9.85%, reflecting short-term headwinds and market rotation away from certain pharmaceutical stocks. The strong weekly and monthly returns in early 2026 indicate a potential recovery phase, but investors should weigh these gains against the broader sector outlook and valuation adjustments.

Conclusion

Lincoln Pharmaceuticals Ltd’s transition from an attractive to a fair valuation grade marks a significant development in its market narrative. While the stock remains reasonably priced relative to earnings and book value, the shift signals that investors are factoring in sector challenges and moderating growth expectations. The company’s solid financial metrics and long-term returns provide a foundation for confidence, but the fair valuation status and Sell Mojo Grade counsel prudence.

Investors should continue to monitor valuation trends, peer comparisons, and sector dynamics to gauge the stock’s future trajectory. For those seeking exposure to the Pharmaceuticals & Biotechnology sector, Lincoln offers a balanced risk-reward profile, but alternative options with superior growth prospects or more attractive valuations may warrant consideration.

Unlock special upgrade rates for a limited period. Start Saving Now →